Statements (26)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:biotechnology
|
gptkbp:CEO |
gptkb:Pablo_J._Cagnoni
|
gptkbp:focus |
cellular therapies
red blood cell therapeutics |
gptkbp:foundedYear |
2013
|
gptkbp:founder |
gptkb:Flagship_Pioneering
|
gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
https://www.w3.org/2000/01/rdf-schema#label |
Rubius Therapeutics
|
gptkbp:industry |
gptkb:biotechnology
|
gptkbp:notableProduct |
gptkb:RUBY-Red_Platform
|
gptkbp:parentCompany |
gptkb:Flagship_Pioneering
|
gptkbp:publiclyTraded |
yes
|
gptkbp:researchArea |
oncology
rare diseases autoimmune diseases |
gptkbp:status |
filed for bankruptcy in 2023
|
gptkbp:stockExchange |
gptkb:NASDAQ
|
gptkbp:stockSymbol |
gptkb:RUBY
|
gptkbp:website |
https://www.rubiustx.com/
|
gptkbp:bfsParent |
gptkb:Arch_Venture_Partners
gptkb:Robert_Samuel_Langer gptkb:Alexandria_Venture_Investments gptkb:Flagship_Pioneering gptkb:Third_Rock_Ventures gptkb:Bob_Langer |
gptkbp:bfsLayer |
6
|